Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call Transcript
This call is being recorded. Welcome to Medivir press conference. For the first part of the conference call, the participants will be in listen only mode. (Operator Instructions) Now I will hand the conference over to CEO, Jens Lindberg. Please go ahead.
Thank you. Good afternoon, and welcome, everyone. My name is Jens Lindberg, I'm the CEO of Medivir. I am joined for today's call by our Chief Medical Officer, Pia Baumann, as well as our Chief Scientific Officer, Fredrik Ãberg, and Magnus Christensen, our CFO. Today's call, we will follow up on the events at last week when we presented our first data for fostrox + Lenvima at a scientific congress at ASCO GI in San Francisco. And go through the data, and also what that means, implications for our plans going forward.
So we are now back in Sweden after a very energizing week with a lot of interactions with global experts in the field of hepatocellular carcinoma. And in the call today, we will focus on three elements. We'll start off with a bit of a sort
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
